Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1

Status

Unknown 2Completed 2

Sponsor Class

OTHER 4INDUSTRY 3UNKNOWN 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4

Conditions

Carcinoma, Non-Small-Cell Lung 88Lung Neoplasms 53Carcinoma, Hepatocellular 43Breast Neoplasms 33Small Cell Lung Carcinoma 29Squamous Cell Carcinoma of Head and Neck 23Cholangiocarcinoma 22Urinary Bladder Neoplasms 21Colorectal Neoplasms 21Pancreatic Neoplasms 20Ovarian Neoplasms 17Triple Negative Breast Neoplasms 16Biliary Tract Neoplasms 16Neoplasm Metastasis 13Head and Neck Neoplasms 12Neoplasms 11Carcinoma, Renal Cell 11Liver Neoplasms 9Endometrial Neoplasms 9Carcinoma, Transitional Cell 9Uterine Cervical Neoplasms 7Esophageal Neoplasms 7Carcinoma, Squamous Cell 7Adenocarcinoma Of Esophagus 7Recurrence 6Prostatic Neoplasms 6Mesothelioma, Malignant 6Melanoma 6Gallbladder Neoplasms 6Fallopian Tube Neoplasms 6

Interventions

Cisplatin 86Radiotherapy 71Paclitaxel 50Fluorouracil 38Carboplatin 36Drug Therapy 32Neoadjuvant Therapy 23toripalimab 19tislelizumab 18pembrolizumab 17camrelizumab 17Irinotecan 17Esophagectomy 17Surgical Procedures, Operative 16Radiation 16Docetaxel 16sintilimab 15Oxaliplatin 14130-nm albumin-bound paclitaxel 14nimotuzumab 11TP protocol 11S 1 (combination) 11Radiotherapy, Intensity-Modulated 11Cetuximab 11Capecitabine 11Albumin-Bound Paclitaxel 10apatinib 9Leucovorin 9Immune Checkpoint Inhibitors 8nedaplatin 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
OTHER × Esophageal Squamous Cell Carcinoma × durvalumab × Clear all
NCT02735239 2024-03-22

Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer

Ludwig Institute for Cancer Research

Phase 1/2 Completed
73 enrolled 18 charts
Gastrointestinal

Adenocarcinoma Of Esophagus, Diabetes Mellitus, Insulin-Dependent, 12, Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT04568200 2024-01-22

Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Resectable Esophageal Squamous Cell Carcinoma

Peking Union Medical College Hospital

Phase 2 Completed
60 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT03377400 2020-12-17

Definitive CCRT Combined With Durvalumab and Tremelimumab for Inoperable Esophageal Cancer

Samsung Medical Center

Phase 2 Unknown
40 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT04054518 2019-08-13

DESC

Instituto do Cancer do Estado de São Paulo

Phase 2 Unknown
22 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡